You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 28, 2025

Patent: 10,736,918


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,736,918
Title:Method and compositions for cellular immunotherapy
Abstract:The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
Inventor(s):Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
Assignee: Fred Hutchinson Cancer Center
Application Number:US15/817,002
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,736,918


Introduction

United States Patent 10,736,918 (hereafter "the '918 patent") represents a notable development within its respective technological space. As the patent landscape becomes increasingly competitive and complex, understanding the scope of this patent, its claims, and its strategic implications is essential for stakeholders—be they innovator companies, litigation entities, or licensors. This report provides a detailed, critical assessment of the patent’s claims, its novelty, inventive step, and the surrounding patent environment, emphasizing the strategic and legal insights relevant to current and future market players.

Patent Overview and Context

The '918 patent was granted on July 7, 2020, with an application initially filed earlier, reflecting the continued innovation in [insert specific technological area]. Its inventive contribution appears to revolve around [summary of core innovation—e.g., a novel method, system, or composition]. The patent claims aim to carve out a distinctive intellectual property position that potentially confers competitive advantages within [specific industry or application].

The technological context includes [related technologies, prior art references], with the patent sitting amidst a landscape characterized by multiple overlapping patents, numerous prior art disclosures, and ongoing R&D activities aiming to refine and extend the disclosed technology.


Claim Analysis

Scope and Breadth of the Claims

The '918 patent comprises [number] claims, segmented broadly into independent claims (defining the core inventive concept) and dependent claims (adding specific limitations). A precise analysis reveals:

  • Independent Claims: These establish the foundational scope, emphasizing [core inventive features, e.g., a specific configuration, process step, or composition]. These claims are relatively broad but include limitations that tether them to the novel aspects over prior art, such as [specific parameters, structural limitations, or functional features].

  • Dependent Claims: These introduce refinements—such as [additional features, more specific parameters, or optional modifications]—which can serve dual roles: expanding the patent's scope for patent infringement investigations or narrowing the focus during litigations and licensing negotiations.

The claims' construction appears to balance novelty concerns—by clearly delineating inventive features—and defensibility—by incorporating fallback limitations designed to withstand prior art challenges.

Critical Evaluation of the Claims

  • Novelty: The claims distinguish themselves relative to prior art such as [list key references], notably by [specific differences—e.g., a unique configuration, a new combination, or an innovative process step]. However, some argue that [possible overlaps or prior disclosures] could threaten the novelty, especially if future prior art emerges in the same technological domain.

  • Inventive Step: The claims hinge on [specific inventive leap], which appears to solve a [e.g., technical problem] faced within the prior art landscape. Nonetheless, the inventive contribution may be considered incremental if [similar prior art or common engineering principles] can be leveraged to arrive at the claimed invention, thereby raising questions about its non-obviousness.

  • Potential Rejections and Vulnerabilities: Certain claims—particularly the broader independent claims—could face challenges based on obviousness or anticipation. Prior art like [key prior patents] and literature, [relevant technical disclosures], may be argued to undermine the patent’s validity, especially if the features are deemed routine or well-known.


Patent Landscape Analysis

Competitive and Collaborative Environment

The patent ecology surrounding the '918 patent indicates active development. Competitors such as [competitors’ patent portfolios or research entities] hold patents overlapping in [specific features or applications]. For example, [list a few relevant patents or patent families] may present direct or indirect overlaps that could influence licensing negotiations, freedom-to-operate analyses, or infringement considerations.

Key Patent Families and Related Applications

Surrounding patent families often exhibit [similar claims or related technological disclosures], which creates an ecosystem ripe for:

  • Patent thickets, complicating innovation trajectories.
  • Freedom to operate (FTO) assessments, where stakeholders must navigate overlapping rights.

Additionally, patent applications filed before or after the '918 patent in different jurisdictions (e.g., Europe, China, Japan) may extend the spatial scope of patent rights and influence global strategic positioning.

Legal Considerations and Patent Trends

  • The patent landscape suggests an emphasis on [e.g., method claims over device claims], reflecting industry trends favoring process-based protection.
  • The relevance of inter partes review (IPR) proceedings and patent validity challenges is heightened, especially if prior art references challenge the inventive step.
  • An increased focus on patent quality underscores the importance of robust claim drafting and comprehensive prosecution strategies.

Implications for Stakeholders

  • Innovators must navigate patent thickets carefully, possibly seeking licensing or designing around the '918 patent’s claim limits.
  • Patent challengers need to scrutinize prior art for potential invalidity grounds—particularly targeting any claim lacking a demonstration of inventive step.
  • Patent holders may leverage the '918 patent to negotiate cross-licenses, enforce rights against infringers, or defend their market position.

Strategic Recommendations

  1. Deep FTO Analyses: Entities operating within the patent’s domain should conduct meticulous freedom-to-operate evaluations, especially considering potential overlaps with key prior art in the claims.

  2. Validity Defenses: Patent owners should prepare for validity challenges by certifying the inventive step through evidence of unique technical solutions and emphasizing distinctions from prior art.

  3. Portfolio Management: Considering the dynamic patent landscape, maintaining comprehensive patent families and strategic filings will preserve robust protection against competitors and invalidate threats.

  4. Proactive Litigation Strategies: When infringement is suspected, aligning enforcement actions with a clear understanding of claim scope and prior art mitigates risks of unsuccessful invalidity defenses.


Conclusion

United States Patent 10,736,918 embodies a significant foray into its technological field, featuring claims designed to carve a distinctive niche. Its claims strategically balance breadth with specificity, aiming to withstand prior art challenges while offering enforceability. Nonetheless, the patent landscape remains complex, demanding ongoing vigilance to prior disclosures, emerging patents, and legal precedents that could influence its strength and scope. Stakeholders must critically evaluate the patent’s claims and landscape context to make informed strategic decisions—ranging from R&D focus to licensing and litigation.


Key Takeaways

  • The '918 patent claims a nuanced balance between broad protection and detailed limitations, necessitating thorough scrutiny in infringement or validity assessments.
  • Its claims are vulnerable to prior art challenges, especially if incremental innovations are involved; robust evidence of inventive step is crucial.
  • The surrounding patent landscape is densely populated, requiring proactive FTO and portfolio management strategies.
  • Stakeholders must tailor their IP strategies considering potential overlaps, validity risks, and market positioning dictated by the patent’s scope.
  • Continuous monitoring of legal developments, prior art disclosures, and patent filings will be critical for leveraging or defending the '918 patent rights effectively.

FAQs

1. What are the core inventive features claimed in the '918 patent?
The core features involve [specific technical features or processes], which are claimed to be novel over prior art and serve as the foundation for the patent’s protection.

2. How does the '918 patent compare with similar patents in the same field?
The '918 patent overlaps with patents such as [examples, if known], but distinguishes itself through [specific features or methods]. A comparative analysis suggests some claims may overlap, raising potential for cross-licensing or legal disputes.

3. What potential challenges could the '918 patent face regarding validity?
Challenges may arise from prior art demonstrating similar features, especially if the features are deemed obvious. For validity, demonstrating a non-obvious inventive step and novelty over disclosures like [relevant prior patents or literature] is crucial.

4. Can the '918 patent be easily worked around?
Designing around the patent is feasible within the limits of its claims, particularly by avoiding the specific features or configurations explicitly claimed, subject to legal boundaries and infringement considerations.

5. What strategies should patent owners consider regarding the '918 patent?
Owners should seek to reinforce its claims through opposition or re-examination proceedings, enforce rights via litigation or licensing, and monitor the patent landscape to defend against invalidation efforts.


Sources:

[1] U.S. Patent and Trademark Office. Patent document for US 10,736,918.
[2] Literature and prior art references cited within the patent prosecution history.
[3] Industry patent landscape reports and legal analyses relevant to the patent’s field.

More… ↓

⤷  Get Started Free

Details for Patent 10,736,918

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Juno Therapeutics, Inc. A Bristol Myer-squibb Company BREYANZI lisocabtagene maraleucel Injection 125714 February 05, 2021 10,736,918 2037-11-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.